What question did this study set out to answer?

Investigate the rapid clinical development of antibody-drug conjugates and associated challenges.

February 2, 2026PLoS Medicine2 citationsOpen Access

Beyond the hype: Antibody-Drug Conjugates are advancing faster than our clinical strategy

GNGiulia Notini GBGiampaolo Bianchini JPJosé Manuel Pérez-García

Key Points

Investigate the rapid clinical development of antibody-drug conjugates and associated challenges.
Analysis of clinical data on antibody-drug conjugates in breast cancer
Evaluation of treatment efficacy across breast cancer subtypes
Assessment of trial designs and drug tolerability
Antibody-drug conjugates show efficacy across all breast cancer subtypes
Rapid clinical expansion raises challenges in treatment strategy
Concerns over trial design and drug tolerability are highlighted

Abstract

Antibody-drug conjugates are redefining treatment options in advanced breast cancer, demonstrating efficacy across all breast cancer subtypes. However, their rapid clinical expansion has resulted in several unresolved challenges, including the need for rational sequencing strategies, appropriate and ethical trial design, drug tolerability, and the limitation of mono-national development programs.

AIに質問

Bookmark

View Full Paper